Parkside Financial Bank & Trust’s Summit Therapeutics SMMT Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$380	Buy	+20	New	+$323	﹤0.01%	2598
2025 Q4	–	Sell	-18	Closed	-$372	–	2790
2025 Q3	$372	Buy	+18	New	+$437	﹤0.01%	2619
2025 Q2	–	Sell	-55	Closed	-$1.06K	–	2976
2025 Q1	$1.06K	Buy	+55	New	+$1.1K	﹤0.01%	2083
2020 Q2	–	Sell	-398	Closed	-$1K	–	1673
2020 Q1	$1K	Hold	398	–	–	﹤0.01%	1327
2019 Q4	$1K	Hold	398	–	–	﹤0.01%	1468
2019 Q3	$1K	Hold	398	–	–	﹤0.01%	1443
2019 Q2	$1K	Hold	398	–	–	﹤0.01%	1449
2019 Q1	$1K	Hold	398	–	–	﹤0.01%	1410
2018 Q4	$0	Buy	+398	New	+$619	﹤0.01%	1562

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parkside Financial Bank & Trust's SMMT Position: Q1 2026 in Review

Parkside Financial Bank & Trust opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 20 shares worth $380. The stake represents ﹤0.01% of the portfolio and ranks #2598 among its holdings. This is a return to the name: Parkside Financial Bank & Trust previously reported a position in SMMT as recently as Q3 2025.

Parkside Financial Bank & Trust first reported a position in SMMT in Q4 2018 and has held it in 9 quarters since. The position peaked at $1.06K in Q1 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Parkside Financial Bank & Trust held 20 shares of Summit Therapeutics worth $380 as of Q1 2026.
Summit Therapeutics was a new Parkside Financial Bank & Trust position in Q1 2026.
Summit Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2598 holding.
Parkside Financial Bank & Trust first reported a position in Summit Therapeutics in Q4 2018 and has held it in 9 quarters since.
Parkside Financial Bank & Trust's Summit Therapeutics position peaked at $1.06K in Q1 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.